Scientific Industries, Inc. filings document the company’s life science tool operations, governance matters and material events tied to its continuing DOTS bioprocessing, VIVID pill counter and Torbal businesses. Recent 8-K and amended 8-K filings cover the completed sale of the Genie Division assets, related pro forma financial information, transition and supply arrangements, and a change in the company’s independent registered public accounting firm.
Proxy filings describe annual meeting voting matters and shareholder governance procedures. Periodic-report notices and Form 10-Q-related disclosures address reporting timing, financial-statement preparation and the company’s formal public-company reporting obligations.
Scientific Industries, Inc. reports first-quarter 2026 results showing higher sales but continued losses as it invests in bioprocessing. Revenue rose to $1,227,100 from $942,300, driven by growth in both Benchtop Laboratory Equipment and Bioprocessing Systems, and gross margin improved to 38.3% from 36.5%.
The loss from continuing operations narrowed to $1,589,300 from $2,057,100, with basic and diluted loss per share improving to $(0.13) from $(0.16), helped by lower general and administrative and selling expenses. Research and development spending increased as new bioprocessing products were developed.
Cash and cash equivalents were $797,800 and investment securities were $4,853,000 as of March 31, 2026. Operating activities used $993,500 of cash in the quarter. Management cites proceeds and follow-on agreements from the 2025 Genie Division sale as support for funding operations for at least one year, while acknowledging an accumulated deficit of $36,740,200 and expected ongoing negative operating cash flows.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options covering 130,000 shares of common stock on February 17, 2026. The options have an exercise price of $0.60 per share, were granted at no purchase cost, and vest on a 4 year cliff from the grant date. Following this award, Santos holds options on a total of 563,388 shares directly. This is a compensation-related grant rather than an open-market share purchase or sale.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options to acquire 50,000 shares of common stock. The options carry an exercise price of $0.60 per share, become exercisable starting on February 17, 2027, and expire on February 17, 2036. According to the disclosure, these options were granted in lieu of salary and vest over one year at a rate of 1/12th per month. After this grant, Santos directly holds 433,388 derivative securities related to the company.
Scientific Industries, Inc. reported full-year 2025 results, highlighted by the sale of its Genie benchtop product line and continued investment in bioprocessing. Net revenues rose to $5,053,800, driven mainly by Torbal weighing products, while dependence on a single pill-counter customer remained high.
The company posted a net loss of $1,220,400, a substantial improvement from 2024 as it recorded a $5,263,400 gain on the Genie sale and reduced general, selling, and R&D expenses. However, gross margin fell to 25.8% due to bioprocessing inventory write-offs.
Cash and equivalents were $955,000 at year-end, with an accumulated deficit of $35,150,900. Management expects existing cash plus proceeds and earn-outs from the Genie transaction to fund operations for at least one year while it pursues growth in its Bioprocessing Systems segment.
SCIENTIFIC INDUSTRIES INC Chairman John A. Moore bought additional shares of the company’s stock. On this Form 4, he reports an open-market purchase of 9,000 shares of Common Stock at a price of $0.58 per share on March 23, 2026.
Following this transaction, Moore directly owns 926,871 shares of Scientific Industries common stock. This filing reflects a net increase in his holdings, as there were no reported sales, option exercises, or derivative transactions in this disclosure.
Scientific Industries Inc. reported a stock option grant to its Chief Financial Officer, Zachary Rovinsky. He received options for 25,000 shares of common stock at an exercise price of $0.6000 per share. These options vest on a 4-year cliff from the grant date, meaning none vest until the four-year mark, when they vest in full.
After this award, he holds a total of 45,000 stock options directly. This is a compensation-related, non-market transaction rather than an open-market purchase or sale of common shares.
Scientific Industries Inc. director Michael Blechman received grants of stock options covering a total of 44,000 shares of common stock on February 17, 2026. The awards consist of 24,000 and 20,000 option shares, each with an exercise price of 0.6000 and expiration on February 17, 2036.
The options were granted in lieu of cash director fees and vest over one year at 1/12 per month, providing compensation rather than reflecting open-market buying. Following these grants, Blechman directly holds 116,186 stock options linked to the company’s common stock.
SCIENTIFIC INDUSTRIES INC Chairman of the Board and director John A. Moore made an open-market purchase of the company’s common stock. He bought 1,000 shares on February 19, 2026 at a price of $0.65 per share. Following this transaction, Moore directly owns 917,871 common shares of Scientific Industries.
Scientific Industries Inc. director and chairman John A. Moore received stock option awards as compensation. He was granted stock options covering 230,000 shares of common stock and an additional 30,000-share option, each with a conversion price of $0.6000 per share.
The filing shows these awards were granted in lieu of cash compensation and vest over one year at a rate of 1/12 per month. Following these grants, Moore holds stock options covering 916,871 shares, giving him additional long-term equity exposure but reflecting routine, compensation-related awards rather than open-market purchases.
Scientific Industries Inc. director John J. Nicols received stock options as compensation instead of cash fees. On February 17, 2026, he was granted stock options covering a total of 140,000 shares of Common Stock, with an exercise price of $0.60 per share and an expiration date of February 17, 2036.
The options vest over one year at a rate of 1/12 per month. Following these awards, Nicols holds 275,778 stock options in total, reflecting routine equity-based director compensation rather than open‑market trading.